S&P 500   3,640.47
DOW   29,225.61
QQQ   271.87
Yes, You Can Negotiate with Franchisors. Here's How.
Biden: By 2030, 50% Of All Vehicles Will Be Electric. Sparking New "Lithium Gold Rush." (Ad)
This Little Known Small Cap Is Up 139%: Is The Stock A Buy?
A Trio of Q3 Winners With Room to Run
Biden: By 2030, 50% Of All Vehicles Will Be Electric. Sparking New "Lithium Gold Rush." (Ad)
2 Casino Stocks Worth Taking a Look At
Asian stocks follow Wall St. higher after UK calms markets
Biden: By 2030, 50% Of All Vehicles Will Be Electric. Sparking New "Lithium Gold Rush." (Ad)
This Small-Cap Healthcare Name Is Outperforming Its Index
What Cintas Can Teach Investors About This Bear Market?
S&P 500   3,640.47
DOW   29,225.61
QQQ   271.87
Yes, You Can Negotiate with Franchisors. Here's How.
Biden: By 2030, 50% Of All Vehicles Will Be Electric. Sparking New "Lithium Gold Rush." (Ad)
This Little Known Small Cap Is Up 139%: Is The Stock A Buy?
A Trio of Q3 Winners With Room to Run
Biden: By 2030, 50% Of All Vehicles Will Be Electric. Sparking New "Lithium Gold Rush." (Ad)
2 Casino Stocks Worth Taking a Look At
Asian stocks follow Wall St. higher after UK calms markets
Biden: By 2030, 50% Of All Vehicles Will Be Electric. Sparking New "Lithium Gold Rush." (Ad)
This Small-Cap Healthcare Name Is Outperforming Its Index
What Cintas Can Teach Investors About This Bear Market?
S&P 500   3,640.47
DOW   29,225.61
QQQ   271.87
Yes, You Can Negotiate with Franchisors. Here's How.
Biden: By 2030, 50% Of All Vehicles Will Be Electric. Sparking New "Lithium Gold Rush." (Ad)
This Little Known Small Cap Is Up 139%: Is The Stock A Buy?
A Trio of Q3 Winners With Room to Run
Biden: By 2030, 50% Of All Vehicles Will Be Electric. Sparking New "Lithium Gold Rush." (Ad)
2 Casino Stocks Worth Taking a Look At
Asian stocks follow Wall St. higher after UK calms markets
Biden: By 2030, 50% Of All Vehicles Will Be Electric. Sparking New "Lithium Gold Rush." (Ad)
This Small-Cap Healthcare Name Is Outperforming Its Index
What Cintas Can Teach Investors About This Bear Market?
S&P 500   3,640.47
DOW   29,225.61
QQQ   271.87
Yes, You Can Negotiate with Franchisors. Here's How.
Biden: By 2030, 50% Of All Vehicles Will Be Electric. Sparking New "Lithium Gold Rush." (Ad)
This Little Known Small Cap Is Up 139%: Is The Stock A Buy?
A Trio of Q3 Winners With Room to Run
Biden: By 2030, 50% Of All Vehicles Will Be Electric. Sparking New "Lithium Gold Rush." (Ad)
2 Casino Stocks Worth Taking a Look At
Asian stocks follow Wall St. higher after UK calms markets
Biden: By 2030, 50% Of All Vehicles Will Be Electric. Sparking New "Lithium Gold Rush." (Ad)
This Small-Cap Healthcare Name Is Outperforming Its Index
What Cintas Can Teach Investors About This Bear Market?
NASDAQ:SURF

Surface Oncology - SURF Stock Forecast, Price & News

$1.07
-0.09 (-7.76%)
(As of 09/29/2022 12:00 AM ET)
Add
Compare
Today's Range
$1.03
$1.10
50-Day Range
$1.03
$1.96
52-Week Range
$1.00
$8.32
Volume
256,148 shs
Average Volume
685,752 shs
Market Capitalization
$62.10 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$10.25

Surface Oncology MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
857.9% Upside
$10.25 Price Target
Short Interest
Healthy
2.64% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
Selling Shares
$38,270 Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($1.25) to ($1.87) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.18 out of 5 stars

Medical Sector

514th out of 1,097 stocks

Biological Products, Except Diagnostic Industry

83rd out of 172 stocks

SURF stock logo

About Surface Oncology (NASDAQ:SURF) Stock

Surface Oncology, Inc., a clinical-stage immuno-oncology company, engages in the development of cancer therapies in the United States. The company develops various antibodies that include NZV930, a fully human immunoglobulin isotype G4 monoclonal antibody for the production of extracellular adenosine; SRF617, a fully human IgG4 monoclonal antibody that inhibits CD39 enzymatic activity for the production of adenosine and the breakdown of adenosine triphosphate; SRF388 targeting interleukin 27; GSK4381562, an antibody targeting CD112R, an inhibitory protein expressed on natural killer and T cells; and SRF114 targeting the chemokine receptor CCR8. Surface Oncology, Inc. has a license agreement with GlaxoSmithKline Intellectual Property (No. 4) Limited to develop, manufacture, and commercialize antibodies that targets SRF813; and license agreement with Vaccinex, Inc. to develop, manufacture, and commercialize antibodies, which targets SRF114. The company was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

Receive SURF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Surface Oncology and its competitors with MarketBeat's FREE daily newsletter.

SURF Stock News Headlines

Surface Oncology: Q2 Earnings Insights
See More Headlines
Receive SURF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Surface Oncology and its competitors with MarketBeat's FREE daily newsletter.

SURF Company Calendar

Last Earnings
11/04/2021
Today
9/30/2022
Next Earnings (Estimated)
11/03/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:SURF
Fax
N/A
Employees
67
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$10.25
High Stock Price Forecast
$12.00
Low Stock Price Forecast
$8.50
Forecasted Upside/Downside
+857.9%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Net Income
$-78,490,000.00
Net Margins
-182.63%
Pretax Margin
-206.11%

Debt

Sales & Book Value

Annual Sales
$2.69 million
Book Value
$2.58 per share

Miscellaneous

Free Float
51,070,000
Market Cap
$62.10 million
Optionable
Not Optionable
Beta
1.64

Key Executives

  • Dr. Robert W. Ross M.D. (Age 48)
    Pres, CEO & Director
    Comp: $813.01k
  • Dr. Vito J. Palombella Ph.D. (Age 59)
    Chief Scientific Officer
    Comp: $633.25k
  • Dr. Alison O'Neill M.D. (Age 61)
    Chief Medical Officer
    Comp: $649.67k
  • Ms. Jessica Fees CPA (Age 51)
    CFO & Treasurer
  • Ms. Theresa R. Boni J.D. (Age 54)
    Gen. Counsel, Sec. & Sr. VP of Legal
  • Ms. Lisa McGrath
    Chief People Officer
  • Mr. Henry C. Rath (Age 51)
    Chief Bus. Officer
  • Ms. Shannon Rourke Devens
    Sr. VP of Devel. Operations













SURF Stock - Frequently Asked Questions

Should I buy or sell Surface Oncology stock right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Surface Oncology in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" SURF shares.
View SURF analyst ratings
or view top-rated stocks.

What is Surface Oncology's stock price forecast for 2022?

2 brokerages have issued 12 month target prices for Surface Oncology's stock. Their SURF share price forecasts range from $8.50 to $12.00. On average, they predict the company's share price to reach $10.25 in the next twelve months. This suggests a possible upside of 857.9% from the stock's current price.
View analysts price targets for SURF
or view top-rated stocks among Wall Street analysts.

How have SURF shares performed in 2022?

Surface Oncology's stock was trading at $4.78 at the beginning of the year. Since then, SURF stock has decreased by 77.6% and is now trading at $1.07.
View the best growth stocks for 2022 here
.

When is Surface Oncology's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 3rd 2022.
View our SURF earnings forecast
.

How were Surface Oncology's earnings last quarter?

Surface Oncology, Inc. (NASDAQ:SURF) issued its earnings results on Thursday, November, 4th. The company reported ($0.44) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.40) by $0.04. The firm earned $0.39 million during the quarter. Surface Oncology had a negative trailing twelve-month return on equity of 48.17% and a negative net margin of 182.63%.

What is Jeff Goater's approval rating as Surface Oncology's CEO?

5 employees have rated Surface Oncology Chief Executive Officer Jeff Goater on Glassdoor.com. Jeff Goater has an approval rating of 100% among the company's employees. This puts Jeff Goater in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Surface Oncology own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Surface Oncology investors own include Pfizer (PFE), CrowdStrike (CRWD), QUALCOMM (QCOM), Fastly (FSLY), Intel (INTC), Hello Group (MOMO), NVIDIA (NVDA), U.S. Xpress Enterprises (USX), Xilinx (XLNX) and Genocea Biosciences (GNCA).

When did Surface Oncology IPO?

(SURF) raised $84 million in an initial public offering (IPO) on Thursday, April 19th 2018. The company issued 6,000,000 shares at $13.00-$15.00 per share. Goldman Sachs, Cowen and Evercore ISI acted as the underwriters for the IPO.

What is Surface Oncology's stock symbol?

Surface Oncology trades on the NASDAQ under the ticker symbol "SURF."

How do I buy shares of Surface Oncology?

Shares of SURF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Surface Oncology's stock price today?

One share of SURF stock can currently be purchased for approximately $1.07.

How much money does Surface Oncology make?

Surface Oncology (NASDAQ:SURF) has a market capitalization of $62.10 million and generates $2.69 million in revenue each year. The company earns $-78,490,000.00 in net income (profit) each year or ($1.29) on an earnings per share basis.

How can I contact Surface Oncology?

Surface Oncology's mailing address is 50 HAMPSHIRE STREET 8TH FLOOR, CAMBRIDGE MA, 02139. The official website for the company is www.surfaceoncology.com. The company can be reached via phone at (617) 714-4096 or via email at ir@surfaceoncology.com.

This page (NASDAQ:SURF) was last updated on 9/30/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.